Share This Page
Litigation Details for AbbVie Inc. v. Sandoz Inc. (D. Del. 2011)
✉ Email this page to a colleague
AbbVie Inc. v. Sandoz Inc. (D. Del. 2011)
| Docket | 1:11-cv-01113 | Date Filed | 2011-11-09 |
| Court | District Court, D. Delaware | Date Terminated | 2014-09-12 |
| Cause | 35:271 Patent Infringement | Assigned To | Sue Lewis Robinson |
| Jury Demand | None | Referred To | Mary Pat Thynge |
| Patents | 6,080,428; 6,469,035 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AbbVie Inc. v. Sandoz Inc.
Details for AbbVie Inc. v. Sandoz Inc. (D. Del. 2011)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2011-11-09 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
AbbVie v. Sandoz (1:11-cv-01113): Litigation Summary, Patent Targets, and Exclusivity Impact
AbbVie Inc. v. Sandoz Inc., case no. 1:11-cv-01113, is a US Hatch-Waxman patent litigation matter filed in 2011. The case concerns AbbVie’s branded drug IP and Sandoz’s US generic entry plans under ANDA. The litigation’s practical business impact is determined by (1) which Orange Book patents were asserted, (2) the effective claim scope upheld or dismissed, and (3) whether any settlement or consent judgment triggered an agreed generic launch date.
Critical limitation: A complete litigation summary (asserted patents, claim constructions, trial or summary-judgment posture, dispositive rulings, and settlement timing) requires access to the case docket and court filings for 1:11-cv-01113. Without those case-specific records, a precise patent-by-patent analysis cannot be produced in a way that is both complete and accurate.
If you require a litigation brief suitable for licensing, litigation strategy, or investment diligence, the docket and order history are the controlling inputs.
What is AbbVie Inc. v. Sandoz Inc. 1:11-cv-01113 about?
Quick answer: It is a Hatch-Waxman patent infringement suit filed by AbbVie against Sandoz in federal court in 2011, challenging Sandoz’s generic drug authorization pathway under the ANDA framework.
What court and procedural track applies
- Case number: 1:11-cv-01113
- Litigation is governed by the Hatch-Waxman Act framework (ANDA + Orange Book patent assertions), which typically involves:
- A complaint alleging infringement of one or more Orange Book-listed patents.
- Sandoz responses asserting invalidity and non-infringement.
- Possible Paragraph IV certifications and statutory remedies (automatic stays or agreed launch dates).
- Potential settlement leading to consent judgments.
What products are typically in-scope in AbbVie v. Sandoz suits
AbbVie frequently litigates in multiple therapeutic areas; case-specific identification of the drug and asserted Orange Book patents is necessary to determine the claims at issue, the formulation or method-of-use coverage, and the generic entry risk.
Which patents were asserted in AbbVie v. Sandoz 1:11-cv-01113 (Orange Book list and counts)?
Quick answer: Not specified in the information provided. Patent-by-patent identification is mandatory to deliver a business-grade analysis of claim scope, validity risk, and expiration-driven launch timing.
What “asserted patents” means in Hatch-Waxman
Litigation typically asserts a subset of patents listed for the reference listed drug (RLD) in the Orange Book, commonly including one or more of:
- Composition-of-matter patents (active ingredient or core chemical series)
- Formulation patents (e.g., specific salts, polymorphs, particle-size distributions, coatings)
- Method-of-use patents (clinical dosing regimen claims)
- Device or delivery system patents (less common for small molecules, more common across biologics and combination products)
Why the exact asserted-patent list matters
- A composition patent shifts the analysis to chemical identity, equivalents, and enablement.
- A formulation patent shifts the analysis to manufacturing process, particle engineering, and bioequivalence-relevant characteristics.
- A method-of-use patent shifts the analysis to labeling, design-around, and infringement under the “use” claim theory.
What is the litigation timeline for AbbVie v. Sandoz 1:11-cv-01113 (filings, key orders, and deadlines)?
Quick answer: Not specified in the information provided. A credible timeline requires dates from the docket, including complaint filing, answers, claim construction orders, summary judgment, trial orders (if any), and final judgments or dismissals.
What a complete Hatch-Waxman timeline typically includes
- Complaint filing date and asserted patent list
- ANDA filing/Paragraph IV certification dates (often referenced in the complaint)
- Markman/claim construction schedule
- Summary judgment or dispositive motions
- Any settlement date and consent judgment entry
- Any FDA approval and commercial launch date milestones
How to read “time to resolution” for exclusivity planning
For generic launch modeling, the decisive dates are usually:
- Final non-appealable court decision date, or
- Date of settlement/consent judgment specifying launch terms.
Without docket dates, the exclusivity impact cannot be computed.
How did the court rule in AbbVie v. Sandoz 1:11-cv-01113 (dismissal, summary judgment, claim construction)?
Quick answer: Not specified in the information provided. Court outcomes are determinative for patent strength scoring and for predicting other generic challengers’ entry windows.
What outcomes drive exclusivity and licensing
- If asserted patents are dismissed as invalid, Sandoz and other generics can accelerate entry risk.
- If non-infringement findings occur based on design-around, other ANDA applicants may still face similar barriers depending on their formulation and labeling approach.
- If infringement is found and injunctions issue, launch is blocked until expiration or appeal.
Did AbbVie and Sandoz settle (consent judgment) and what launch date did the agreement set?
Quick answer: Not specified in the information provided. Settlement terms, including:
- agreed effective launch date,
- permitted interim marketing,
- non-designated claims, and
- geographic or product-form constraints, are core to business planning.
Why settlement terms beat general assumptions
Hatch-Waxman settlement agreements often produce the real-world “when can generics sell” timeline regardless of patent expiration schedules. A settlement can:
- narrow the asserted set of patents,
- cap design-around options,
- or permit delayed entry even where patents remain in dispute.
What is the Paragraph IV status for Sandoz in AbbVie v. Sandoz 1:11-cv-01113?
Quick answer: Not specified in the information provided. Paragraph IV status must map to the asserted Orange Book patents and the certification content.
How Paragraph IV affects the statutory 30-month stay
In general:
- A Paragraph IV certification triggers a 30-month stay unless earlier than final decision.
- A final court decision earlier/later changes the actual entry window.
But calculating this without the certification and ruling dates is not feasible.
What is the Orange Book status of the drug involved in AbbVie v. Sandoz 1:11-cv-01113?
Quick answer: Not specified in the information provided. Orange Book listing and patent expiry dates are required to connect the litigation to exclusivity.
What this section must include for decision-grade analysis
- RLD name and NDA/ANDA linkage
- Orange Book patent numbers asserted
- Patent expiration dates and any pediatric exclusivity extensions
- Regulatory exclusivities that may still block entry even if some patents fall
How strong is the patent estate in AbbVie v. Sandoz 1:11-cv-01113 (validity and enforceability posture)?
Quick answer: Not specified in the information provided. A strength assessment requires:
- outcome rulings (invalid/non-infringed vs infringement found),
- claim construction results,
- prosecution history impacts, and
- any appeal disposition.
What “patent strength” means in Hatch-Waxman
Actionable factors include:
- breadth of claim construction,
- how close accused product is to claim limitations,
- prior art gap and anticipation/obviousness findings,
- whether there are enforceability defenses (inequitable conduct, written description, indefiniteness).
No docket findings are available in the provided input.
Does the litigation affect biosimilar or generic entry risk beyond Sandoz?
Quick answer: Not specified in the information provided. Hatch-Waxman actions primarily affect the specific ANDA applicant(s) and the specific patents at issue, but precedential holdings can influence other litigations.
What to map to assess spillover
- Claim construction adopted by the court and whether other courts may follow it
- Validity outcomes
- Whether the decision resolved broad core limitations that multiple generics must address
How does AbbVie v. Sandoz compare with other AbbVie vs generic litigations filed around 2011?
Quick answer: Not specified in the information provided. A comparative landscape requires:
- the same AbbVie RLD or therapeutic area,
- the same Sandoz portfolio,
- and the same litigation outcomes and deadlines.
Key Takeaways
- AbbVie Inc. v. Sandoz Inc. (1:11-cv-01113) is a Hatch-Waxman patent infringement dispute filed in 2011.
- The business-critical items for an actionable litigation brief are not present in the input: asserted patent numbers, Orange Book linkage, procedural milestones, court rulings, and any settlement/consent judgment terms.
- Without those docket-specific records, a definitive infringement/validity summary and exclusivity impact analysis cannot be produced.
FAQs
1) What determines the generic launch date after AbbVie sues under Hatch-Waxman?
The deciding factor is usually a final non-appealable judgment or a settlement/consent judgment specifying an effective launch date, plus the Orange Book patent and exclusivity landscape tied to the asserted patents.
2) What is the most important document in AbbVie vs Sandoz patent litigation?
The docket orders that identify the asserted patents and the court’s dispositive rulings, including any claim construction results and final judgment or consent decree.
3) Can another generic launch before the AbbVie v. Sandoz case ends?
It depends on whether that applicant’s ANDA is stayed by a different Paragraph IV certification, whether court decisions remove the stay, and whether a settlement agreement covers or excludes other filers.
4) What happens if the court narrows claim scope at claim construction?
Narrow claim scope can create non-infringement paths for design-arounds that meet the narrowed limitations, changing both the litigation posture and settlement leverage.
5) How does patent expiry differ from statutory exclusivity in Hatch-Waxman?
Patent expiry ends enforceable patent exclusivity for those patents, while regulatory exclusivities (and any listed patents with later expiry) can still block entry until their respective end dates or until litigation eliminates enforceable barriers.
References (APA)
No sources were provided or retrievable from the prompt content for case-specific docket details; therefore no citations can be listed.
More… ↓
